Detected ·
Delix Therapeutics
$100MSeries C
Delix Therapeutics closed an oversubscribed $100M Series C, led by Johnson & Johnson Innovation JJDC and SV Health Investors' Dementia Discovery Fund, to advance Zalsupindole into Phase II and its broader TrueNeuroplastogen pipeline.
- Website
- —
- linkedin.com/company/76400524
- Amount
- $100 000 000 USD
- Stage
- Series C
- Event
- Funding round
- Detected
- 2026-11-10 08:07:49 UTC
- Signal ID
- 4bdace38-6f0d-47a3-ad89-f12018e441a3
As the API returns it
{
"id": "4bdace38-6f0d-47a3-ad89-f12018e441a3",
"created_at": "2026-11-10T08:07:49.484549Z",
"company_name": "Delix Therapeutics",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/76400524",
"event_type": "funding",
"funding_amount": 100000000,
"funding_currency": "USD",
"funding_stage": "series_c",
"message": "*Delix Therapeutics closed an oversubscribed $100M Series C, led by Johnson & Johnson Innovation JJDC and SV Health Investors' Dementia Discovery Fund, to advance Zalsupindole into Phase II and its broader TrueNeuroplastogen pipeline.*"
}